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Abstract: The importance of immunoglobulin E (IgE) in atopic
disorders such as asthma, allergic rhinitis, food allergies, and atopic
dermatitis is well established. Elevation of total serum IgE is typi-
cally found in many atopic patients, and in predisposed individuals,
allergen-speciﬁc IgE is produced. The availability of humanized
monoclonal antibodies against IgE has provided a new therapeutic
option and tool to explore the role IgE in allergic diseases and the
effects of inhibiting IgE itself. Omalizumab is a humanized, mono-
clonal antibody that recognizes and binds to the Fc portion of the IgE
molecule. Administration of omalizumab results in a rapid and sub-
stantial decrease in free IgE in serum. Consequently, the activity of
cell populations involved in allergic inﬂammation, including mast
cells, eosinophils, basophils, and antigen-presenting cells, is affected
as well. Clinically, anti-IgE therapy has already been proven to be
useful in the treatment of asthma and allergic rhinitis. The aim of this
review is to provide an overview of the mechanisms of action of anti-
IgE therapy as well as its efﬁcacy in the treatment of allergic diseases,
especially asthma. Considerations regarding dosing and safety of
omalizumab will be addressed as well.
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BACKGROUND
Immunoglobulin E (IgE), originally described in 1967 by
Ishizaka et al,1 is well established to be important in atopic
disorders such as asthma, allergic rhinitis, food allergies, and
atopic dermatitis. Immunoglobulin E binds to the high-
afﬁnity IgE receptor, Fc?RI, and is subsequently expressed on
the surface of a number of key inﬂammatory cells, including
mast cells, basophils, and dendritic cells. When allergen binds
to the Fab portion of the IgE molecule, cross-linking of 2
adjacent IgE molecules on the surface of allergic effector cells
(in particular mast cells and basophils) initiates intracellular
signaling pathways that result in the release of preformed and
newly synthesized mediators. This type 1 hypersensitivity
reaction is central to the pathogenesis of atopic disorders2
(Fig. 1).
Thus far, chronic therapy for allergic diseases has largely
been limited to blocking the effects of speciﬁc mediators (eg,
leukotriene modiﬁers and anti-histamines) or the use of cor-
ticosteroids to reduce the consequences of mediator release on
the inﬂammatory cascade. More recently, however, the
availability of humanized monoclonal antibodies against IgE
has provided a new therapeutic option and tool to more closely
explore the role of IgE in allergic diseases and the effects of
inhibiting IgE itself.
Omalizumab is a humanized, monoclonal antibody that
recognizes and binds to IgE. Approximately 5% of omalizu-
mab is composed of murine sequences (the antigen recogni-
tion portion of the molecule) that were engrafted onto a human
IgG1J framework (Fig. 2).3Y5 Omalizumab binds to the CH3
domain of the IgE molecule, which is conserved among all
IgE molecules.6 This is the same site by which IgE binds to
Fc?RI. Because omalizumab binds to the same site that IgE
molecules use to attach to Fc?RI, it cannot cross-link cell
surface-expressed IgE. Thus, omalizumab can bind only to
soluble IgE and therefore cannot precipitate degranulation of
effector cells via this mechanism.7
IgE and IgE Receptors
Immunoglobulin E is present in the serum in far lesser
amounts than IgG, IgM, or IgA. The half-life of IgE in the
serum is only 2 days. The expression of Fc?RI on the surface
of critical effector cells, such as basophils, is up-regulated by
IgE. This effect likely occurs through the direct interaction of
IgE with Fc?RI>.8 Another IgE receptor, Fc?RII (CD23),
whose role is less certain, binds with much lower afﬁnity to
IgE. Fc?RII seems to have opposing effects dependent on
whether the molecule is expressed on the cell surface or exists
free in the serum. Soluble Fc?RII up-regulates the production
of IgE through interaction with CD21 in the B-cell coreceptor.
In contrast, ligation of cell surface-expressed Fc?RII by IgE
seems to inhibit IgE production.9
MECHANISM OF ACTION
Administration of omalizumab results in a rapid and
substantial decrease in free IgE in serum.10 By virtue of this
dramatic reduction in serum-free IgE levels, omalizumab
decreases the expression of Fc?RI on several cell types.10Y13 A
99% reduction in free serum IgE levels has been noted within
2 hours of omalizumab administration. Furthermore, within
3 months of therapy, human basophil responsiveness (hista-
mine releasability) was reduced by 90%.11 Omalizumab ad-
ministration results in reductions in allergen-induced nasal
challenge responses and expression of Fc?RI on basophils
within 7 days.11
Antigen presentation by dendritic cells is facilitated by
the surface expression of Fc?RI.14 Two subtypes of dendritic
cells, DC1 and DC2, seem to be instrumental in the phenotypic
development of Th1 and Th2 cells, respectively.15 The
expression of Fc?RI on dendritic cells is greater in patients
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with asthma than nonatopic controls and correlates with serum
IgE levels.16 In ragweed-sensitive patients with seasonal
allergic rhinitis treated with omalizumab, both DC1 and DC2
cells showed a signiﬁcant decrease in Fc?RI expression as early
as day 7 that persisted through day 42 of treatment. The
decrease in Fc?RI expression also correlated with a decrease in
serum-free IgE as well as basophil Fc?RI expression.12 Recent
data showed that omalizumab reduces Fc?R1 expression on
monocytes as well.17 These results suggest that omalizumab
may have a signiﬁcant effect on the sensitization phase of the
allergic response by regulation of Fc?RI expression on
dendritic cells and monocytes.
Unlike the rapid decrease in Fc?RI expression induced
on basophils and dendritic cells, omalizumab’s effect on
cutaneous mast cell Fc?RI expression seems to occur more
gradually. A small study evaluated the effect of omalizumab
on intradermal allergen skin test titration and on Fc?RI
expression in skin biopsy samples. Omalizumab had no effect
on Fc?RI on day 7; however, by day 70, there was a 90%
reduction in Fc?RI expression in skin biopsy specimens.
There was no change in the number of tryptase-positive cells
in the biopsy specimens. The authors interpreted this as an
omalizumab-induced decrease in the expression of Fc?RI by
cutaneous mast cells.13 In general, omalizumab has aweak and
delayed effect on allergen-induced immediate skin test
responses. This has resulted in the unreliability of skin test
responses as a surrogate biomarker to regulate and explore
dosing effects of this agent. However, the inhibitory effects of
omalizumab on late-phase skin responses are more rapid and
profound.13,18
Omalizumab’s Effects on Markers of
Airway Inﬂammation
Nitric oxide (NO) has been identiﬁed as an important
noninvasive marker of airway inﬂammation in patients with
asthma. The effects of omalizumab on exhaled NO have been
examined in 29 children with moderate-to-severe allergic
asthma. Subjects randomized to omalizumab showed a sig-
niﬁcant reduction in exhaled NO from baseline to the end of
the 52-week study period (P = 0.032) despite a substantial
reduction in the dose of inhaled corticosteroids.19
Omalizumab treatment reduces blood eosinophil levels
in patients with seasonal allergic rhinitis correlating with
reduced levels of serum-free IgE.20 Similar decreases in both
blood and sputum eosinophils compared with baseline values
have been seen in patients with allergic asthma during
FIGURE 1. Immunoglobulin E and the allergic cascade
(IL indicates interleukin; Sxs, symptoms). After allergen
sensitization, cytokines stimulate B cells to produce
allergen-speciﬁc IgE. Immunoglobulin E molecules then
circulate and bind to high-afﬁnity IgE receptors (Fc?RI) on the
surface of mast cells and basophils. Activation of mast cells and
basophils by cross-linking of the surface IgE molecules leads
to degranulation and release of mediators. Adapted from
Brownell and Casale.2
FIGURE 2. Omalizumab structure. Omalizumab is a recombinyant humanized monoclonal antibody composed of 95% human
sequence and 5% murine sequence. *CDR indicates complementarity-determining region. Adapted from Boushey.3
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omalizumab therapy.21,22 Omalizumab treatment has also been
shown to decrease B-lymphocyte counts under experimental
conditions. No signiﬁcant differences were noted in the other
lymphocyte subpopulations.23
Omalizumab’s effect on inﬂammatory cells in bronchial
biopsies as well as on sputum eosinophils has been evaluated.
Forty-ﬁve patients with mild-to-moderateYpersistent asthma
with sputum eosinophilia more than 2% were treated with
omalizumab (n = 22) or placebo (n = 23) for 16weeks. Subjects
underwent sputum induction and bronchoscopy with bronchial
biopsy before and after treatment. Treatment with omalizumab
resulted in a signiﬁcant decrease in the mean percentage of
sputum eosinophils from 6.6% to 1.7% (P = 0.05 vs placebo).
This was associated with a signiﬁcant reduction in tissue
eosinophils; cells positive for Fc?R1; CD3+, CD4+, and CD8+
T lymphocytes; B lymphocytes; and cells staining positive for
interleukin 4 (IL-4); but not improvement in airway hyperre-
sponsiveness to methacholine.24 The dichotomy between
omalizumab’s effects on airway inﬂammation versus hyperre-
sponsiveness suggested to the authors that IgE and/or
eosinophils may not be causally linked to airway hyperrespon-
siveness to methacholine in mild-to-moderate asthma. Oma-
lizumab has shown inconsistent effects on airway
hyperresponsiveness.24Y26 However, consistent with the lung
anti-inﬂammatory effects of omalizumab, early proof of con-
cept studies documented the ability of omalizumab to inhibit
both early and late allergen-induced airway responses and the
consequent increase in sputum eosinophils.21,26
Thirty-ﬁve patients with moderate-to-severe allergic
asthma were treated with omalizumab in addition to baseline
ICS, and circulating cytokines were measured. Levels of IL-13
were signiﬁcantly decreased in omalizumab compared with
placebo-treated patients, whereas IL-5 and IL-8 had non-
signiﬁcant decreases. Levels of IL-6, IL-10, and s-ICAM were
unchanged with omalizumab therapy.22
Another possible mechanism of action involves the
potential of omalizumab to promote mast cell apoptosis. The
binding of different IgE molecules to Fc?RI induces a spec-
trum of activation events in the absence of antigen. Highly
cytokinergic IgEs induced production of cytokines and ren-
dered mast cells resistant to apoptosis in an autocrine
fashion.27 Thus, by decreasing IgE and Fc?R1 expression,
omalizumab might lead to mast cell apoptosis, but this has not
yet been demonstrated.
Omalizumab treatment has been shown to induce
human eosinophil apoptosis in patients with allergic asthma.
After 12 weeks of therapy with omalizumab, markers of eo-
sinophil apoptosis (annexin V) were signiﬁcantly increased. In
addition, fewer GM-CSF+, IL-2+, and IL-13+ lymphocytes
were evident in omalizumab versus placebo-treated allergic
asthma patients.28 Figures 3 and 4 illustrate the mechanisms
of action summarized in Table 1.29
OMALIZUMAB DISEASE-SPECIFIC EFFECTS
Asthma
A number of studies have established the efﬁcacy and
safety of omalizumab for the treatment of patients with
moderate-to-severe asthma leading to the US Food and Drug
Administration’s (FDA) approval of omalizumab for the
treatment of moderate-to-severe persistent allergic asthma in
patients 12 years or older.
Three phase 3 trials were conducted on a total of 1405
patients with moderate-to-severe allergic asthma.30Y32 Two
trials were conducted in subjects 12 years and older treated
with inhaled corticosteroids.30,32 The third trial was conducted
in children aged 6 to 12 years old receiving inhaled corti-
costeroids.31 During the initial 16 weeks, omalizumab was
added on to inhaled corticosteroids at a stable dose. Subjects
then underwent a steroid-reduction phase lasting 12 weeks.
Doses of corticosteroids were reduced by up to 25% every
2 weeks to the lowest level required for optimal disease
control.
FIGURE 3. Omalizumab mechanisms of action.
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A reduction in asthma exacerbations when compared
with placebo was shown in all 3 studies. Furthermore, oma-
lizumab demonstrated a corticosteroid-sparing effect in all 3
studies. In addition, fewer asthma symptoms, less rescue
medication usage, and improved quality-of-life scores were
noted in the omalizumab-treated patients. In the adolescent
and adult studies, omalizumab resulted in small but statisti-
cally signiﬁcant improvements in peak expiratory ﬂow and
forced expiratory volume in 1 second (FEV1).
32
The data from these 3 studies were later pooled to de-
termine the effect of omalizumab on serious asthma exacer-
bations.33 Signiﬁcantly fewer unscheduled outpatient visits
and emergency-room visits were observed in the omalizumab-
treated patients compared with placebo. Hospitalizations were
also signiﬁcantly reduced from 3.42 events per 100 patient-
years on placebo to 0.26 on omalizumab treatment.
To examine baseline characteristics predictive of a res-
ponse to omalizumab, data from 1070 adolescents and adults
from 2 of these phase 3 trials were pooled.34 Patients with
features suggestive of greater disease severity seemed to
obtain the greatest beneﬁt from the addition of omalizumab to
their therapeutic regimen. These included patients with a
history of emergency treatment of asthma in the last year,
patients on 800 Kg or greater inhaled beclomethasone per day,
and patients with an FEV1 65% or less of predicted. The
greatest beneﬁts were noted in patients who had 2 or more of
these characteristics.
Of 1412 patients in phase 3 trials, 254 patients were
identiﬁed as high risk (ever required intubation, visited an
emergency room, required overnight hospitalization, or re-
ceived treatment in an ICU during the last year). Most the
high-risk patients had undergone an emergency room admis-
sion with only a small proportion requiring ICU care and/or
intubation. In these high-risk patients on the steroid-stable
phase of the studies, those treated with omalizumab had a
reduction in signiﬁcant asthma exacerbation episodes by 56%.
In addition, these high-risk patients treated with omalizumab
were less likely to be rehospitalized due to asthma while dem-
onstrating improvements in peak ﬂows and asthma symptoms.
Omalizumab prevented exacerbations in approximately 17
additional patients for every 100 treated. Fifty percent of
potential exacerbations were prevented by treatment with
omalizumab, and 5.7 patients were needed to be treated with
omalizumab to maintain 1 patient free of an exacerbation.35
Patients with severe allergic asthma who required high-
dose ﬂuticasone (Q1000 Kg/d) with or without oral corticos-
teroids were treated with omalizumab. At 32 weeks, a
signiﬁcant reduction in the dose of inhaled corticosteroids
was noted in the omalizumab group when compared with
placebo (mean, 57.2% vs 43.3%; P = 0.003). Improved
symptoms, less rescue medication usage, and improved
quality of life were also observed in the omalizumab group
when compared with placebo.36 However, no signiﬁcant
reduction in exacerbations was observed in this study.
In practice, omalizumab is typically added to the
therapeutic regimen in patients who remain poorly controlled
despite maximal medical therapy. It is these more severe
patients with asthma that are at greatest risk of serious
complications and mortality.37 The addition of omalizumab to
maximal conventional asthma therapy was evaluated in a 52-
week trial. The study involved 312 symptomatic patients with
moderate-to-severe allergic asthma who were symptomatic
despite treatment with high doses of inhaled corticosteroids
plus long-acting A2-agonists, anti-leukotrienes, or oral ster-
oids.38 Compared with placebo, the omalizumab group
showed a greater reduction of asthma exacerbations (60%),
unscheduled physician visits, and days missed from work or
school. A similar study evaluated 419 patients with severe
uncontrolled asthma despite high dose of inhaled corticoster-
oids and long acting bronchodilators. Patients were random-
ized to receive omalizumab or placebo for 28 weeks in a
double-blind, parallel-group fashion.39 Omalizumab therapy
signiﬁcantly reduced the rate of signiﬁcant exacerbations
while decreasing emergency visits by 44%. In addition,
quality-of-life scores, pulmonary functions, and asthma symp-
tom scores improved with omalizumab add on therapy.
Another report evaluated the pooled data from 5 double-
blind trials and 2 open-label studies for an analysis of the effect
of add-on therapy with omalizumab on asthma exacerbations
in severe patients with asthma.40 A total of 4308 patients were
included (2511 treated with omalizumab). Omalizumab
decreased the rate of asthma exacerbations by 38% and also
decreased the rate of emergency visits by 47%. Taken together,
FIGURE 4. Omalizumab mechanisms of action. Omalizumab/
anti-IgE decreases free IgE, IgE bound to Fc?RI, and Fc?RI
expression on mast cells, basophils, dendritic cells, and
monocytes. It also reduces tissue inﬁltration by T and B
lymphocytes, eosinophils, mast cells, and basophils.
TABLE 1. Omalizumab: Summary of Effects on Airway
Inﬂammation
Decreases free serum IgE
Decreases expression of Fc?RI (on mast cells, basophils, dendritic cells,
and monocytes)
Decreases eosinophils (serum, sputum, bronchial biopsies)
Decreases B lymphocytes




Adapted from Stokes and Casale.29
WAO Journal & October 2008 Anti-IgE Therapy
* 2008 World Allergy Organization 177
these studies suggest that omalizumab is effective as an add-on
therapy in severe patients with asthma that are poorly
controlled despite maximal medical therapy. A summary of
the effects noted in patients with allergic asthma treated with
omalizumab is shown in Table 2.29
Allergic Rhinitis
The effect of omalizumab was evaluated in patients with
ragweed-sensitive allergic rhinitis.41 Patients were randomized
to receive 1 of 3 doses of omalizumab or placebo. Subjects
treated with 300 mg omalizumab every 3 to 4 weeks dem-
onstrated signiﬁcantly lower nasal symptoms scores, rhinitis
quality-of-life scores, and days missed from work or school
when compared with placebo during the pollen season. In
addition, signiﬁcant correlations were observed between the
dose of omalizumab, reduction in serum IgE and improve-
ments in nasal symptoms, and rescue antihistamine use.
Another large seasonal allergic rhinitis study examined
the therapeutic beneﬁts of omalizumab in birch-pollenY
sensitive rhinitics.42 The omalizumab-treated group showed
signiﬁcant improvements over placebo in average daily
symptom scores, usage of rescue antihistamines, and quality-
of-life measures during birch season. A signiﬁcant decrease in
basal tumor necrosis factor > and albumin in the nasal lavage
ﬂuid (a marker of vascular permeability) was also shown in
omalizumab-treated seasonal allergic rhinitis patients.43
Similar clinical efﬁcacy was demonstrated by a double-
blind, randomized, placebo-controlled study involving nearly
100 patients treated with either omalizumab (n = 48) or
placebo (n = 50) during Japanese cedar pollen season.44 A
later publication by the same authors directly compared the
effect of omalizumab to suplatast tosilate, a drug that
selectively inhibits the Th2 cytokine production from T cells,
in controlling rhinoconjunctival symptoms associated with
Japanese cedar pollen. The authors concluded that omalizu-
mab was superior in preventing and controlling symptoms
and reducing rescue medication use.45
Omalizumab was also shown to be effective in the
treatment of perennial allergic rhinitis when patients with
moderate-to-severe disease were evaluated.46 However, the
magnitude of effect was small. The multiple upper airway
improvements noted with omalizumab therapy are seen in
Table 3.29
Allergic rhinitis and asthma frequently coexist. Poor
control of rhinitis may exert a detrimental effect on asthma.47
Several studies have demonstrated improved asthma control
when concomitant allergic rhinitis is properly treated.47Y50
The SOLAR study evaluated adolescents and adults with
moderate-to-severe asthma on stable asthma and rhinitis ther-
apy who also had persistent allergic rhinitis.51 Fewer asthma
exacerbations were observed in the omalizumab-treated
patients than placebo-treated patients (20.6% vs 30.1%).
Furthermore, more patients in the omalizumab group demon-
strated a clinically signiﬁcant improvement in both asthma
and rhinitis quality-of-life indices (57.7% vs 40.6%). This
suggests omalizumab is effective in the treatment of upper
and lower airway symptoms in the same patients.51
Omalizumab Plus Immunotherapy
The rationale for using the combination of anti-IgE and
allergen immunotherapy comes from preexisting data about
the biologic and immunologic effects of both therapies. The
immunomodulatory effects of immunotherapy are due to a
number of proposed mechanisms, including blunting of seas-
onal increases in IgE levels, increasing allergen-speciﬁc IgG
levels, shifting the balance of T-lymphocyte subsets away from
a Th2 phenotype and toward a Th1 phenotype, and production
of IL-10.52Y57 However, immunotherapy is associated with the
risk of allergic reactions to the extract injections.
The addition of omalizumab to standard maintenance
dose immunotherapy was evaluated in 221 children and ad-
olescents with sensitization to birch and grass allergen.58
During birch season, both birch and grass immunotherapy plus
omalizumab groups had decreased symptoms by 39% in the
group treated with irrelevant immunotherapy (grass) and by
48% in the birch immunotherapy group compared with
irrelevant immunotherapy and placebo. Similar results were
seen in grass season with irrelevant (birch) immunotherapy and
omalizumab decreasing symptoms by 45%, whereas patients
on grass immunotherapy and omalizumab had a reduction in
symptom scores by 71% compared with irrelevant immu-
notherapy and placebo. When these ﬁndings were further
analyzed for the grass-pollenYallergic children, it was noted
that omalizumab plus immunotherapy-treated groups had
signiﬁcantly diminished rescue medication usage and number
of symptomatic days when compared with either omalizumab
or immunotherapy alone.59 The combined treatment with both
omalizumab and grass immunotherapy wasmore effective than
omalizumab alone.
The primary objective of a more recent study was to
determine whether omalizumab, given 9 weeks before rush
immunotherapy, followed by 12weeks of dual omalizumab and
immunotherapy was more effective than rush immunotherapy
TABLE 2. Omalizumab: Demonstrated Clinical Effects
on Asthma
Decreased inhaled corticosteroid doses
Decreased asthma symptoms
Decreased rescue medication usage
Decreased exacerbations
Decreased emergency room visits
Decreased hospitalizations
Improved pulmonary functions (small effect)
Increased quality of life
Adapted from Stokes and Casale.29
TABLE 3. Omalizumab: Clinical Effects on Allergic Rhinitis
Decreased daily symptoms
Decreased rescue medication usage
Increased quality of life
Decreased nasal allergen challenge responses
Decreased missed school or work days
Adapted from Stokes and Casale.29
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followed by immunotherapy alone in ragweed-allergic
patients.60 A major secondary objective was whether omali-
zumab improved the safety of rush immunotherapy. Omalizu-
mab improved both the efﬁcacy and the safety of
immunotherapy. Patients receiving omalizumab plus immu-
notherapy had fewer adverse events than those receiving im-
munotherapy alone. Post hoc analysis of groups receiving
immunotherapy demonstrated that the addition of omali-
zumab resulted in a 5-fold decrease in risk of anaphylaxis
caused by RIT (odds ratio, 0.17; P = 0.026). On an intention-to-
treat basis, patients receiving both omalizumab and immu-
notherapy showed a signiﬁcant improvement in severity scores
during the ragweed season compared with those receiving
immunotherapy alone (0.69 vs 0.86; P = 0.044). Thus, com-
bined therapy with omalizumab and allergen immunotherapy
may be an effective strategy to permit more rapid and higher
doses of allergen immunotherapy to be given more safely and
with greater efﬁcacy to patients with allergic diseases.60
Atopic Dermatitis
Atopic dermatitis is a chronic inﬂammatory disease of
the skin that affects 10% to 20% of children and 1% to 3% of
adults.61 In the allergic form of atopic dermatitis, serum total
IgE is elevated.62 A few small-scale reports of omalizumab
therapy have demonstrated conﬂicting results. A small study
reported on 3 patients with severe atopic dermatitis and
baseline IgE levels of 1990, 2890, and 6120 IU/mL. All of the
patients noted signiﬁcant improvement on omalizumab
(150Y450 mg every 2 weeks for 12 weeks) as early as 2
weeks after therapy was initiated.63 Another study evaluated 7
patients with asthma, allergic rhinitis, and atopic dermatitis.
Their baseline IgE levels ranged from 262 to 2020 IU/mL.
Eczema symptoms were scored before therapy and after 3 and
7 months of omalizumab. Six of the 7 patients had at least
moderate disease before the start of therapy but only 5 com-
pleted 7 months of therapy due to problems with insurance
coverage for treatment. Improvement was noted within the
ﬁrst 3 months of therapy. Of the 5 remaining patients at 7
months, 3 had resolution of their eczema and 2 had only mild
disease.64
Another small study of 3 adult patients with severe
atopic dermatitis and concomitant asthma, allergic rhinitis, or
both were treated with omalizumab 450 mg every 2 weeks.65
After 4 months of therapy, no improvement was noted in
their atopic dermatitis symptoms. The baseline values of IgE
before treatment were extremely elevated (5440, 23000, and
24400 IU/mL).65 In a pilot investigation published recently,
low-dose omalizumab (150 mg every 2 weeks) demonstrated
promising results in some of the patients with generalized
atopic dermatitis. Serum total IgE levels of all patients were
well over 1000 IU/mL before treatment (range, 1343Y39,534
IU/mL). Six patients responded with satisfying to very good
clinical response based on scoring (Scoring Atopic Dermatitis
[SCORAD]). On the other hand, 5 patients showed either no
relevant changes or clinical deterioration at the conclusion
of the study (10 cycles of treatment).66 On the basis of the
limited data available, the role for omalizumab in the treatment
of atopic dermatitis requires further investigation.
Food Allergy
Food allergies affect approximately 6% of children under
the age of 3 years and 2% of adults, with 1.5 million
experiencing peanut allergy in the United States alone.67,68 The
only treatment currently available is strict elimination and
avoidance, but unintended ingestion still accounts for 50 to 100
deaths a year in the United States due to peanut products.67
Another humanized IgG1 monoclonal antibody against IgE,
TNX-901, was evaluated in peanut allergy patients. A double-
blind, placebo-controlled, randomized trial in 84 patients with
proven peanut hypersensitivity evaluated 3 doses of TNX-901
given every 4weeks for 16 weeks. Themean baseline threshold
of sensitivity to peanut ﬂour was 178 to 436 mg for all the
groups, which was equivalent to 1/2 to 11/2 peanuts ingested.
By the end of treatment, all groups including the placebo group
had a greater threshold of peanut tolerability, but only the high-
dose TNX-901 group had a signiﬁcant improvement from a
threshold dose of 178 mg (one-half peanut) to 2805 mg (nearly
9 peanuts). However, 25% of the high-dose group had
no improvement. There is very little data on the effects of
omalizumab on food allergies, and it is not yet approved for this
indication. Table 4 summarizes the potential effects of anti-IgE
therapy atopic dermatitis and food allergy.29
Other
Since becoming widely available, clinicians have
exploited omalizumab’s immunomodulating properties in
the management of several other IgE-mediated disorders as
evidenced by case reports. Examples include using the pro-
tective effects of omalizumab during venom immunotherapy in
a patient who would otherwise be unable to tolerate the
immunotherapy.69,70 Other clinical scenarios in which anti-IgE
treatment shows promise include chronic rhinosinusitis,71
nasal polyposis,72 chronic urticaria,73,74 idiopathic angioe-
dema,75 eosinophil-associated gastrointestinal disorders,76
mastocytosis,69,77 latex allergy,78 and allergic bronchopulmon-
ary aspergillosis.79
DOSING
The only FDA-approved anti-IgE therapy is omalizumab
(Xolair). The dosing regimen is based on a patient’s body
weight and total serum IgE level. The recommended dose is
0.016 mg/kg body weight per international unit of IgE every 4
weeks, administered subcutaneously at either 2- or 4-week
intervals for adults and adolescents (persons 12 years and
older) with moderate-to-severe perennial allergic asthma.80
For asthma, patients may need a trial of at least 12 weeks
before clinical improvement is apparent.81
Omalizumab is absorbed slowly, reaching peak serum
concentrations after an average of 7 to 8 days with no speciﬁc
uptake of omalizumab by any organ or tissue. In asthma
patients, omalizumab serum elimination half-life averaged 26
days. Omalizumab is cleared via IgG as well as elimination of
omalizumab/IgE complexes via the liver.80
Serum total IgE levels (ie, bound and unbound) increase
after the ﬁrst dose due to the formation of omalizumab/IgE
complexes, which have a slower elimination rate compared
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with free IgE. Total IgE levels increased with omalizumab
therapy up to 5-fold after 1 month and more than 8 times
before omalizumab levels after 3 months of therapy while free
IgE levels decreased.82
The role for eventual dose reduction or cessation of
omalizumab remains unclear. A recent study that examined the
effects of omalizumab dose reduction and cessation concluded
that the marked reduction in serum IgE levels was not
maintained at lower doses.83 In general, after discontinuation
of omalizumab dosing, the omalizumab-induced increase in
total IgE and decrease in free IgE were reversible. Total IgE
levels may take up to a year to achieve pretreatment levels
after discontinuation of omalizumab.80
Beneﬁcial clinical effects, however, may persist for a
considerable time despite discontinuing omalizumab. Eigh-
teen patients whose omalizumab was stopped after 6 years
of treatment were subsequently followed for 12 to 14 months.
Six to 14 months after discontinuing omalizumab, most of
the cat- and mite-allergic patients with asthma (13 patients)
noted their asthma symptoms to be improved or the same as
while on treatment with omalizumab with little or no increase
in other asthma medications. Basophil sensitivity to allergen
was correspondingly lower (as compared with 15 allergic
control subjects) even 12 to 14 months after omalizumab
withdrawal as well.84 These observations may be a reﬂection
of the duration these patients were treated with omalizumab
and deserve further investigation.
SAFETY
Omalizumab has proven to be a generally well-tolerated
medication. The most common adverse event is a local reaction
at the injection site that may include burning, pruritis, hives,
pain, redness, induration, swelling, warmth, and bruising. In
patients with asthma receiving omalizumab or placebo, a local
cutaneous reaction was observed in 45% and 43% of subjects,
respectively. Severe local cutaneous reactions occurred in 12%
of omalizumab-treated subjects and 9% of placebo-treated
subjects.80,85 Other frequent adverse events in patients treated
with omalizumab were viral infections (23%), sinusitis (16%),
headaches (15%), and pharyngitis (11%). These events
occurred at similar rates in omalizumab-treated patients and
control patients.80 Only 6.6% of the total adverse events were
felt to be treatment related in the omalizumab group versus
5.6% in the placebo group. Six tenths of a percent of
omalizumab-treated patients and 1.1% of placebo-treated
patients withdrew from clinical trials due to adverse events.
The safety of omalizumab was evaluated in more than
300 children in a randomized, double-blind, placebo-con-
trolled study.86 Subjects were treated for 28 weeks followed by
a 24-week open label extension. In patients who underwent 52
weeks of treatment with omalizumab, upper respiratory
infections and headaches were the most commonly encoun-
tered adverse events (47.1% and 42.7%, respectively). During
the double-blind 28-week treatment period, the incidence rate
of events was similar between omalizumab and placebo.
Urticaria was reported in eleven patients (4.9%). With the
exception of 1 severe case of urticaria that necessitated
withdrawal from the study, all patients with urticaria had either
spontaneous remission or resolution with antihistamine
treatment. Adverse event incidence during the open label
extension was similar to the omalizumab-treated group during
the 28-week double-blind phase. The results of this study
suggested that omalizumab is well tolerated in children and
has a good safety proﬁle.
There were 4127 patients in the original studies who
received omalizumab. Of these, 19 (0.46%) developed cancer,
whereas 2236 patients received placebo treatment and 5
(0.22%) of this group developed cancer.85 There were 3726
patients in controlled clinical trials who received omalizumab.
Of these, 0.35% developed cancer. None of the differences
between these groups were statistically signiﬁcant. All tumors
but 1 (a recurrent non-Hodgkin lymphoma) were solid tumors.
Thus, it is very likely thatmost of these tumorswere preexistent.
Indeed, a history of cancer was not an exclusion criterion if
greater than 3 months before enrollment in the initial studies.
Overall, the conclusion of an independent panel of oncologists
when they compared the cancer rates for those reported in this
population range was that there was no relative risk that was
statistically signiﬁcant for treatment with omalizumab. None-
theless, postapproval surveillance is appropriate.
In the clinical trials, there was no increase in type 1
hypersensitivity adverse events with an overall incidence of
urticaria 1.2% (39/3224) in the omalizumab group and 1.1%
(24/2019) in control patients.87 Clinical trial data documented
no evidence of any immune complex disease associated with
omalizumab treatment, and in 1723 patients studied, only 1
demonstrated anti-omalizumab antibodies. Postmarketing
reports have, however, noted 1 case of serum sickness at-
tributed to omalizumab88 and 1 case of severe thrombocyto-
penia. Thrombocytopenia has been added to potential adverse
events associated with omalizumab although no causal
relationship was established, and routine platelet monitoring
is not required. In addition, rare cases of alopecia have been
reported (G0.1%), but no causal relationship to omalizumab
has been established.80
Important to note, rare cases of acute systemic reactions
have occurred after omalizumab treatment. These events
occurred after the ﬁrst and multiple doses and usually did
not manifest until at least 60 minutes after injection. The
mechanisms are unclear.87 An analysis of anaphylaxis
associated with the use of Xolair (omalizumab) was recently
published by the Omalizumab Joint Task Force (OJTF). The
OJTF is an executive committee formed by the American
Academy of Allergy, Asthma and Immunology (AAAAI) and
the American College of Allergy, Asthma and Immunology
TABLE 4.
Omalizumab and atopic dermatitis
Improved symptoms in some patients
Likely not effective for patients with extremely elevated serum IgE levels
Anti-IgE antibody therapy on food allergy
Only high-dose therapy significantly improved amount of food allergen
tolerated
Has not been evaluated with omalizumab
Adapted from Stokes and Casale.29
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(ACAAI) that reviewed omalizumab clinical trials and
postmarketing surveillance data on anaphylaxis and anaphy-
lactoid reactions. The OJTF report included recommendations
for physicians who prescribe omalizumab. A summary of
the AAAAI/ACAAI OJTF recommendations is included in
Table 5. Reviewed data included omalizumab clinical
trials and postmarketing reports ﬁled between June 2003
and December 2005, including those ﬁled with the US FDA.
The OJTF concluded that during a period when 39,510
patients were receiving omalizumab, there were 41 episodes of
anaphylaxis associated with omalizumab administration. This
corresponded to an anaphylaxis reporting rate of 0.09% of
patients. The OJTF also analyzed the timing of the 41
anaphylactic events. Twenty-two (61%) of these reactions
occurred in the ﬁrst 2 hours after 1 of the ﬁrst 3 doses. After
the fourth dose, most anaphylactic events occurred within 30
minutes of omalizumab administration. On the basis of the
timing of these events, the OJTF suggested observation of
patients for 2 hours after the ﬁrst 3 omalizumab treatments and
30 minutes for subsequent injections. Furthermore, adminis-
tering physicians and other licensed health care providers
should have the medications, equipment, and staff to ap-
propriately treat anaphylaxis. Patients taking omalizumab
should be trained in the recognition of signs and symptoms of
anaphylaxis and in the use of the epinephrine autoinjector.89
A separate analysis of adverse events reported to the
US FDA and to the manufacturers of Xolair (omalizumab)
took into account events occurring through December 2006.
One hundred twenty-four cases of anaphylaxis were identiﬁed
and characterized; the estimated number of patients treated
during this time was approximately 57, 300. As in the previous
analysis, time to onset of anaphylaxis varied widely. One third
of cases occurred within 30 minutes of dose administration.
Another 1/3 occurred from 30 minutes to 6 hours. The
remainder presented more than 6 hours after dose administra-
tion. There were also reports of protracted and recurrent
episodes. These cases served as the basis for changes in
prescribing information including the addition of a Boxed
Warning.90
An additional concern with decreasing serum IgE would
be the potential for increased incidence or severity of
helminthic infections. A 1-year clinical trial in Brazil was
performed with 68 patients treated with omalizumab and 69
placebo controls. The odds ratio for helminth infection was
1.47 (95% conﬁdence interval, 0.74Y2.95) indicating that a
patient who had infection was anywhere from 0.74 to 2.95
times as likely to have received omalizumab as a patient who
did not have an infection. Response to antihelminth therapy
was not different between treatment groups. Patients at high
risk of helminthic infection should be monitored for infection
while on omalizumab therapy.91
CONCLUSIONS
Selective anti-IgEYhumanized monoclonal antibody
represents a novel and important therapeutic option for severe
asthma and other allergic diseases. The data suggest that
omalizumab inhibits activation of mast cells and basophils
and decrease the effects of other inﬂammatory cells such
as eosinophils through a variety of mechanisms. This has re-
sulted in clinical improvements in patients with moderate-to-
severe allergic asthma, including signiﬁcant reductions in
exacerbations. Omalizumab seems to be a relatively safe and
generally well-tolerated medication. In years to come, the role
of omalizumab or other anti-IgE antibody strategies in
pediatric asthma, nonallergic asthma, food allergy, atopic
dermatitis, chronic urticaria with autoantibodies to IgE or the
high-afﬁnity IgE receptor, allergic bronchopulmonary asper-
gillosis, and chronic hyperplastic sinusitis and as an adjuvant to
allergen immunotherapy will evolve.
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